Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis By Investing.com

”Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET”

BRIDGEWATER, N.J., May 27, 2024 /PRNewswire/ — Insmed (NASDAQ:) Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. The Company plans to issue a press release sharing the topline results at approximately 6:30 am ET tomorrow, prior to the start of the conference call.

Conference Call

Shareholders and other interested parties may participate in the conference call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) and referencing access code 1245105. The call will also be webcast live on the Company’s website at www.insmed.com.

A replay of the conference call will be accessible approximately one hour after its completion through  June 27, 2024, by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) and referencing access code 1245105. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company’s website at  www.insmed.com.

About  Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is a first-in-disease therapy approved in  the United States,  Europe, and  Japan  to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing.  Insmed is headquartered in  Bridgewater,  New Jersey, with additional offices and research locations throughout  the United States,  Europe, and  Japan. Visit  www.insmed.com  to learn more.

Contact:

Investors:

Bryan DunnExecutive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com  

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com  

Media:

Mandy FaheyExecutive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com